Skip to content
Intelence(etravirine)
Intelence (etravirine) is a small molecule pharmaceutical. Etravirine was first approved as Intelence on 2008-01-18. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Intelence (generic drugs available since 2021-06-14)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etravirine
Tradename
Company
Number
Date
Products
INTELENCEJohnson & JohnsonN-022187 RX2008-01-18
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
intelenceNew Drug Application2020-10-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AG: Non-nucleoside reverse transcriptase inhibitors
— J05AG04: Etravirine
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2071035226
HivD006678O98.74162215
Hepatitis bD006509———1—1
Chronic hepatitis cD019698EFO_0004220B18.2———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv-1D015497—53——8
PregnancyD011247EFO_0002950Z33.1——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acquired immunodeficiency syndromeD000163EFO_0000765B2012———3
InfectionsD007239EFO_000054411———2
Hiv-2D015498—1——12
Friedreich ataxiaD005621Orphanet_95G11.11—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
PharmacokineticsD0105991————1
MycosesD009181B35-B491————1
Insulin resistanceD007333EFO_00026141————1
InflammationD0072491————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sleep wake disordersD012893G47————11
Hepatitis cD006526B19.2————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameETRAVIRINE
INNetravirine
Description
Etravirine is an aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directly to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities It has a role as a HIV-1 reverse transcriptase inhibitor and an antiviral agent. It is a dinitrile, an organobromine compound, an aminopyrimidine and an aromatic ether.
Classification
Small molecule
Drug classantivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br
Identifiers
PDB—
CAS-ID269055-15-4
RxCUI475969
ChEMBL IDCHEMBL308954
ChEBI ID63589
PubChem CID193962
DrugBankDB06414
UNII ID0C50HW4FO1 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,768 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
154,690 adverse events reported
View more details